Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

Clicks: 339
ID: 120846
1997
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Monthly administration of 750 mg/kg of RSV-IGIV was safe and well tolerated and was effective in reducing the incidence and total days of both RSV hospitalization and overall respiratory hospitalization in infants with a history of prematurity or bronchopulmonary dysplasia or both.
Reference Key
1997pediatricsreduction Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;
Journal pediatrics
Year 1997
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8989345
Keywords
respiration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine female male Infant newborn Clinical Trial Randomized Controlled Trial Double-Blind Method immunoglobulins intravenous / therapeutic use* length of stay placebos Artificial respiratory syncytial virus infections / prevention & control* hospitalization premature* respiratory syncytial virus infections / complications* bronchopulmonary dysplasia / complications* pmid:8989345 doi:10.1542/peds.99.1.93 respiratory syncytial virus infections / rehabilitation

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.